Compared with Enbrel
, additional species were found in all three Infinitam batches, and of particular note, the chromatograms we obtained by UPLC were similar to the chromatogram in Figure 1(a), as presented by Figure 3(b) of Miranda-Hernandez et al.
The drugs include AbbVie's (NYSE: ABBV) Humira (adalimumab), Pfizer's (NYSE: PFE) Enbrel
(etanercept) and Janssen's Stelara (ustekinumab).
Rheumatoid arthritis (RA) patients are more influenced by the direct-to-consumer campaigns of Xeljanz (Pfizer), Humira (AbbVie) and Enbrel
(Amgen) than any other biological treatment, according to a survey of U.S.
A biosimilar of etanercept received clearance for marketing from the Food and Drug Administration in late August for all of the inflammatory disease indications held by the reference originator etanercept product, Enbrel
, according to an announcement from the agency.
The US will experience major brand erosion beginning with Humira in 2016, followed by Remicade in 2018 and Stelara in 2023; Enbrel
is protected until 2028.
Rheumatoid arthritis (RA) patients with higher baseline levels of type I interferon proteins are more likely to respond to therapy with tumor necrosis factor (TNF) antagonists, such as Enbrel
, Humira and Remicade, according to a study published in the February 2010 issue of Arthritis & Rheumatism.
(Thousand Oaks CA) and Wyeth's (Madison NJ) Enbrel
Amgen and Wyeth are informing physicians of the revised label on etanercept (Enbrel
) via a "Dear Healthcare Professional" letter.
and Mylotarg, biological products launched in Japan in 2005, are helping to drive WKK's rapid growth.
The safety of the biologic etanercept (Enbrel
) doesn't appear to vary depending on the age of the patient taking it for a rheumatic disease, according to the findings from a review of 22 clinical trials.
The National Institute of Clinical Excellence (NICE) has given its stamp of approval to Remicade (infliximab) and Enbrel
Like the two tumor necrosis factor (TNF)-[alpha] inhibitors, etanercept (Enbrel
) and infliximab (Remicade), anakinra is not approved as a first-line therapy but is reserved for patients who have failed to respond to other disease-modifying antirheumatic drugs.